Search Results - "Sattler, Martin"

The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC) by Salgia, Ravi, Pharaon, Rebecca, Mambetsariev, Isa, Nam, Arin, Sattler, Martin

“…KRAS is a frequent oncogenic driver in solid tumors, including non-small cell lung cancer (NSCLC). It was previously thought to be an “undruggable” target due…”
Get full text

Rescue of Hippo coactivator YAP1 triggers DNA damage–induced apoptosis in hematological cancers by Cottini, Francesca, Hideshima, Teru, Xu, Chunxiao, Sattler, Martin, Dori, Martina, Agnelli, Luca, ten Hacken, Elisa, Bertilaccio, Maria Teresa, Antonini, Elena, Neri, Antonino, Ponzoni, Maurilio, Marcatti, Magda, Richardson, Paul G, Carrasco, Ruben, Kimmelman, Alec C, Wong, Kwok-Kin, Caligaris-Cappio, Federico, Blandino, Giovanni, Kuehl, W Michael, Anderson, Kenneth C, Tonon, Giovanni

“…Tumor cells of epithelial origin present rampant DNA damage but do not undergo apoptosis due to inactivation of TP53. Understanding the mechanisms by which…”
Get full text

Inhibition of USP10 induces degradation of oncogenic FLT3 by Weisberg, Ellen L, Schauer, Nathan J, Yang, Jing, Lamberto, Ilaria, Doherty, Laura, Bhatt, Shruti, Nonami, Atsushi, Meng, Chengcheng, Letai, Anthony, Wright, Renee, Tiv, Hong, Gokhale, Prafulla C, Ritorto, Maria Stella, De Cesare, Virginia, Trost, Matthias, Christodoulou, Alexandra, Christie, Amanda, Weinstock, David M, Adamia, Sophia, Stone, Richard, Chauhan, Dharminder, Anderson, Kenneth C, Seo, Hyuk-Soo, Dhe-Paganon, Sirano, Sattler, Martin, Gray, Nathanael S, Griffin, James D, Buhrlage, Sara J

“…An inhibitor of the deubiquitinase (DUB) USP10 regulates the degradation of oncogenic FLT3, thus defining USP10 as a DUB for FLT3 and providing a therapeutic…”
Get full text

Novel Therapeutic Targets and Immune Dysfunction in Malignant Pleural Mesothelioma by Lapidot, Moshe, Saladi, Srinivas Vinod, Salgia, Ravi, Sattler, Martin

“…Advances in the treatment of malignant pleural mesothelioma (MPM) have been disappointing, despite the apparent need for new therapeutic options for this rare…”
Get full text

Anti‐SARS‐CoV‐2 activity of targeted kinase inhibitors: Repurposing clinically available drugs for COVID‐19 therapy by Boytz, RuthMabel, Słabicki, Mikołaj, Ramaswamy, Sita, Patten, J. J., Zou, Charles, Meng, Chengcheng, Hurst, Brett L., Wang, Jinhua, Nowak, Radosław P., Yang, Priscilla L., Sattler, Martin, Stone, Richard M., Griffin, James D., Gray, Nathanael S., Gummuluru, Suryaram, Davey, Robert A., Weisberg, Ellen

“…Coronavirus disease 2019 (COVID‐19) remains a major public health concern, and vaccine unavailability, hesitancy, or failure underscore the need for discovery…”
Get full text

Fragmentation of the mitochondrial network in skin in vivo by Mellem, Daniel, Sattler, Martin, Pagel-Wolff, Sonja, Jaspers, Sören, Wenck, Horst, Rübhausen, Michael Alexander, Fischer, Frank

“…Mitochondria form dynamic networks which adapt to the environmental requirements of the cell. We investigated the aging process of these networks in human skin…”
Get full text

Correction: Mcl-1 confers protection of Her2-positive breast cancer cells to hypoxia: therapeutic implications by Bashari, Muhammad Hasan, Fan, Fengjuan, Vallet, Sonia, Sattler, Martin, Arn, Melissa, Luckner-Minden, Claudia, Schulze-Bergkamen, Henning, Zörnig, Inka, Marme, Frederik, Schneeweiss, Andreas, Cardone, Michael H, Opferman, Joseph T, Jäger, Dirk, Podar, Klaus

Get full text

Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia by Yoda, Akinori, Yoda, Yuka, Chiaretti, Sabina, Bar-Natan, Michal, Mani, Kartik, Rodig, Scott J, West, Nathan, Xiao, Yun, Brown, Jennifer R, Mitsiades, Constantine, Sattler, Martin, Kutok, Jeffrey L, DeAngelo, Daniel J, Wadleigh, Martha, Piciocchi, Alfonso, Dal Cin, Paola, Bradner, James E, Griffin, James D, Anderson, Kenneth C, Stone, Richard M, Ritz, Jerome, Foà, Robin, Aster, Jon C, Frank, David A, Weinstock, David M

“…The prognosis for adults with precursor B-cell acute lymphoblastic leukemia (B-ALL) remains poor, in part from a lack of therapeutic targets. We identified the…”
Get full text

c-Met and hepatocyte growth factor: potential as novel targets in cancer therapy by Sattler, Martin, Salgia, Ravi

“…Receptor tyrosine kinases have come to fruition as therapeutic targets in a variety of malignancies. In this group of targets, the c-Met receptor tyrosine…”
Get full text

YAP1 maintains active chromatin state in head and neck squamous cell carcinomas that promotes tumorigenesis through cooperation with BRD4 by Chen, Nana, Golczer, Gabriel, Ghose, Subhoshree, Lin, Brian, Langenbucher, Adam, Webb, Jason, Bhanot, Haymanti, Abt, Nicholas B., Lin, Derrick, Varvares, Mark, Sattler, Martin, Egloff, Ann Marie, Joh, Richard, Uppaluri, Ravindra, Emerick, Kevin S., Lawrence, Michael S., Saladi, Srinivas Vinod

“…Analysis of The Cancer Genome Atlas and other published data of head and neck squamous cell carcinoma (HNSCC) reveals somatic alterations of the Hippo-YAP…”
Get full text

Rac2-MRC-cIII–generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors by Nieborowska-Skorska, Margaret, Kopinski, Piotr K., Ray, Regina, Hoser, Grazyna, Ngaba, Danielle, Flis, Sylwia, Cramer, Kimberly, Reddy, Mamatha M., Koptyra, Mateusz, Penserga, Tyrone, Glodkowska-Mrowka, Eliza, Bolton, Elisabeth, Holyoake, Tessa L., Eaves, Connie J., Cerny-Reiterer, Sabine, Valent, Peter, Hochhaus, Andreas, Hughes, Timothy P., van der Kuip, Heiko, Sattler, Martin, Wiktor-Jedrzejczak, Wieslaw, Richardson, Christine, Dorrance, Adrienne, Stoklosa, Tomasz, Williams, David A., Skorski, Tomasz

“…Chronic myeloid leukemia in chronic phase (CML-CP) is induced by BCR-ABL1 oncogenic tyrosine kinase. Tyrosine kinase inhibitors eliminate the bulk of CML-CP…”
Get full text

Chimeric Antigen Receptor T Cell Therapy in Acute Myeloid Leukemia: Trials and Tribulations by Garg, Swati, Ni, Wei, Griffin, James D., Sattler, Martin

“…Acute myeloid leukemia (AML) is a heterogeneous hematological malignancy that is often associated with relapse and drug resistance after standard chemotherapy…”
Get full text

Effect of tree shelters on the survival and growth of coniferous tree species in Central South Bulgaria by Petkova, Krasimira, Iliev, Nasko, Borisov, Martin, Sattler, Martin

“…The effects of tree shelters on the survival, height and diameter growth of three coniferous tree species - Scots pine ( Pinus sylvestris L.), Norway spruce (…”
Get full text

small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma by Podar, Klaus, Tonon, Giovanni, Sattler, Martin, Tai, Yu-Tzu, LeGouill, Steven, Yasui, Hiroshi, Ishitsuka, Kenji, Kumar, Shaji, Kumar, Rakesh, Pandite, Lini N, Hideshima, Teru, Chauhan, Dharminder, Anderson, Kenneth C

“…A critical role for vascular endothelial factor (VEGF) has been demonstrated in multiple myeloma (MM) pathogenesis. Here, we characterized the effect of the…”
Get full text

Dual therapeutic targeting of MYC and JUNB transcriptional programs for enhanced anti-myeloma activity by Lind, Judith, Aksoy, Osman, Prchal-Murphy, Michaela, Fan, Fengjuan, Fulciniti, Mariateresa, Stoiber, Dagmar, Bakiri, Latifa, Wagner, Erwin F., Zwickl-Traxler, Elisabeth, Sattler, Martin, Kollmann, Karoline, Vallet, Sonia, Podar, Klaus

“…Deregulation of transcription factors (TFs) leading to uncontrolled proliferation of tumor cells within the microenvironment represents a hallmark of cancer…”
Get full text

Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097 by Weisberg, Ellen, Halilovic, Ensar, Cooke, Vesselina G, Nonami, Atsushi, Ren, Tao, Sanda, Takaomi, Simkin, Irene, Yuan, Jing, Antonakos, Brandon, Barys, Louise, Ito, Moriko, Stone, Richard, Galinsky, Ilene, Cowens, Kristen, Nelson, Erik, Sattler, Martin, Jeay, Sebastien, Wuerthner, Jens U, McDonough, Sean M, Wiesmann, Marion, Griffin, James D

“…The tumor suppressor p53 is a key regulator of apoptosis and functions upstream in the apoptotic cascade by both indirectly and directly regulating Bcl-2…”
Get full text

BRD9 degraders as chemosensitizers in acute leukemia and multiple myeloma by Weisberg, Ellen, Chowdhury, Basudev, Meng, Chengcheng, Case, Abigail E., Ni, Wei, Garg, Swati, Sattler, Martin, Azab, Abdel Kareem, Sun, Jennifer, Muz, Barbara, Sanchez, Dana, Toure, Anthia, Stone, Richard M., Galinsky, Ilene, Winer, Eric, Gleim, Scott, Gkountela, Sofia, Kedves, Alexia, Harrington, Edmund, Abrams, Tinya, Zoller, Thomas, Vaupel, Andrea, Manley, Paul, Faller, Michael, Chung, BoYee, Chen, Xin, Busenhart, Philipp, Stephan, Christine, Calkins, Keith, Bonenfant, Debora, Thoma, Claudio R., Forrester, William, Griffin, James D.

“…Bromodomain-containing protein 9 (BRD9), an essential component of the SWI/SNF chromatin remodeling complex termed ncBAF, has been established as a therapeutic…”
Get full text

Ethnic Differences and Functional Analysis of MET Mutations in Lung Cancer by KRISHNASWAMY, Soundararajan, KANTETI, Rajani, NICOLAE, Dan L, ZHENG OUYANG, JIE LIANG, MINNA, John, KOZLOFF, Mark F, FERGUSON, Mark K, NATARAJAN, Viswanathan, WANG, Yi-Ching, GARCIA, Joe G. N, VOKES, Everett E, DUKE-COHAN, Jonathan S, SALGIA, Ravi, LOGANATHAN, Sivakumar, WANQING LIU, MA, Patrick C, SATTLER, Martin, SINGLETON, Patrick A, RAMNATH, Nithya, INNOCENTI, Federico

“…Purpose: African Americans have higher incidence and poorer response to lung cancer treatment compared with Caucasians. However, the underlying molecular…”
Get full text

Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML) by Walz, Christoph, Sattler, Martin

“…Imatinib mesylate (Gleevec) was developed as the first molecularly targeted therapy that specifically inhibits the BCR–ABL tyrosine kinase activity in patients…”
Get full text

Mcl-1 confers protection of Her2-positive breast cancer cells to hypoxia: therapeutic implications by Bashari, Muhammad Hasan, Fan, Fengjuan, Vallet, Sonia, Sattler, Martin, Arn, Melissa, Luckner-Minden, Claudia, Schulze-Bergkamen, Henning, Zörnig, Inka, Marme, Frederik, Schneeweiss, Andreas, Cardone, Michael H, Opferman, Joseph T, Jäger, Dirk, Podar, Klaus

“…Molecular mechanisms leading to the adaptation of breast cancer (BC) cells to hypoxia are largely unknown. The anti-apoptotic Bcl-2 family member myeloid cell…”
Get full text